TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05271331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESP block with saline
Description: Bilateral ultrasound guided injection of saline in the erector spinae plane (below erector spinae plane muscle group and above the transverse process of the vertebra)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wound infiltration with saline
Description: Blinded injection of saline in the skin, subcutaneous tissue and muscles at the site of surgical incision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESP block with local anesthetic
Description: Bilateral ultrasound guided injection of local anesthetic (ropivacaine 0.35%, 40ml) in the erector spinae plane (below erector spinae plane muscle group and above the tranverse process of the vertebra)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration with local anesthetic
Description: Blinded injection of local anestetic (ropivacaine 0.35%, 40ml) in the skin, subcutaneous tissue and muscles at the site of surgical incision.
Study: NCT05832749

Intervention type: DEVICE
Intervention: Ophtesis Bio 3% ophthalmic viscosurgical device
Description: Intraocular surgery of the anterior segment, including cataract extraction and intraocular lens (IOL) implantation. The viscoelastic properties of OphtesisBio 3.0% allow lubrication, support and protection of ocular tissues during ophthalmic surgery. Maintains the depth of the anterior chamber during surgery, allows for efficient manipulation with reduced trauma to the corneal endothelium and other surrounding tissues.

Intervention type: DEVICE
Intervention: Healon Endocoat 3% ophthalmic viscosurgical device
Description: Healon@ EndoCoat OVD is an ophthalmic viscoelastic containing 3% sodium hyaluronate indicated for use as a surgical aid in patients undergoing ophthalmic anterior segment procedures including:~* Cataract surgery with an intraocular lens~* Cataract surgery without an intraocular lens~* Secondary intraocular lens implantation~Healon@ EndoCoat maintains a deep chamber during anterior segment surgery, aids in tissue manipulation during surgery, enhances visualization during the surgical procedure and protects the corneal endothelium and other ocular tissue. The viscoelasticity of the solution maintains the normal position of the vitreous face and prevents formation of a flat chamber during surgery. It may also be used to coat intraocular lenses and insertion instruments prior to intraocular lens implantation.
Study: NCT06536556

Intervention type: OTHER
Intervention: First Assessment
Description: pre-treatment assessment

Intervention type: OTHER
Intervention: First Assessment
Description: pre-treatment assessment

Intervention type: OTHER
Intervention: First Assessment
Description: pre-treatment assessment

Intervention type: OTHER
Intervention: Second Assessment
Description: 4 days post-treatment assessment
Study: NCT05836688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Focused Emotion-Regulation Therapy (GET)
Description: Patients will be asked to identify value-derived goals (i.e., goals for the most important domains of one's life) and ones sufficiently important to sustain movement toward them in the short-term future. Patients will discuss their goal possibilities, providing a forum to ensure that goals are manageable and consistent with identified values. Patients will learn strategies to refine their goals (e.g., approaching goals rather than avoiding obstacles, defining markers of progress), generate pathways to goals, and address potential obstacles and blockages. The overall goal is to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Supportive Listening
Description: ISL sessions will be matched in terms of time and attention. Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience. This will be delivered in the same manner as GET (individually) and is a common, non-directive control method in intervention research.
Study: NCT05699382

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: practiced mindfulness through the application for 6 weeks
Description: Physicians working at a tertiary hospital were recruited and randomly divided into two groups, a study group (SG) in which participants practiced mindfulness through the application for 6 weeks
Study: NCT05454696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients in the exercise group will participate in online clinical pilates exercise sessions under the supervision of a physiotherapist twice a week. The exercises will be done via the Zoom application and will continue for 6 weeks. The exercise program will last one hour with a warm-up and cool-down period. The exercises will be done by adhering to the basic principles of clinical pilates. The exercise program includes mat exercises that provide general body strengthening and stretching. Progression will be provided according to the health status of the patients and their compliance with exercise. The intensity of exercise will be planned as medium according to the Rating of perceived exertion (RPE) Scale.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: online physical activity counselling
Description: CG will receive online physical activity counselling by a physiotherapist only once. The importance of physical activity after surgery and the points to be considered during physical activity will be explained to the patients.
Study: NCT06677957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin will be administered together with Rosuvastatin as a drug cocktail as specified for the respective period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin will be administered together with Rosuvastatin as a drug cocktail as specified for the respective period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divarasib
Description: Divarasib will be administered in combination with Digoxin and Rosuvastatin as specified for the respective period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin will be administered together with Digoxin as a drug cocktail as specified for the respective period
Study: NCT06536556

Intervention type: OTHER
Intervention: Second Assessment
Description: 4 days post-treatment assessment

Intervention type: OTHER
Intervention: Second Assessment
Description: 4 days post-treatment assessment
Study: NCT04851795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supervised physical exercise sessions
Description: Participants assigned to the supervised exercise group will perform a supervised routine of approximately 30 minutes, 2 days per week (Monday and Wednesday at the Txagorritxu hospital, and Tuesday and Thursday at the Santiago hospital from 7:15 to 7:45 and from 15:15 to 15:45).

Intervention type: OTHER
Group type: OTHER
Intervention: unsupervised physical exercise
Description: For the non-supervised group, we will propose climbing the stairs from floor 0 to floor 7 three times during the working day and doing planks and stretching exercises outside of work. For the latter, an educational session will be given at the beginning of the study to explain how to perform them correctly.
Study: NCT06677957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin will be administered together with Digoxin as a drug cocktail as specified for the respective period
Study: NCT06002386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vsling
Description: Implantable ventricular repair device
Study: NCT06460441

Intervention type: DIAGNOSTIC_TEST
Intervention: SUNRISE© device
Description: The device under study is the Sunrise© sensor, a single-use Class IIa medical device with CE marking and ISO 13485 certification.~The system combines a mandibular movement sensor with an artificial intelligence program to collect and interpret data. It consists of a three-gram device that is placed on the chin using an adhesive. The sensor is linked to a (free) mobile app, enabling data to be sent to the Sunrise© company's secured platform at the end of the night, and results to be transmitted to the prescribing physician.
Study: NCT06754475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-volume, high-intensity interval training
Description: Low-volume, high-intensity interval training with an arm ergometer will be given two days a week for a total of eight weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Standart medical treatment
Description: Standart medical teatment
Study: NCT06756867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand massage with violet oil
Description: In this study, individuals receiving hemodialysis treatment will be massaged with 2% violet oil for 5-7 minutes on the hand on the non-fistula arm during the dialysis session, 3 times a week for six weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: hand massage with jojoba oil
Description: Hand massage with jojoba oil for hemodialysis patients 3 times a week for 6 weeks
Study: NCT06757075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 10 mg/kg/dose of ibuprofen will be given every 6 hours for 24 hours post surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 10 mg/kg/dose of ibuprofen will be given every 6 hours for 24 hours post surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 10 mg/kg/dose of ibuprofen will be given every 6 hours for 24 hours post surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetominophen
Description: 15 mg/kg/dose of acetominophen will be given every 6 hours for 24 hours post surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetominophen
Description: 15 mg/kg/dose of acetominophen will be given every 6 hours for 24 hours post surgery
Study: NCT06756971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be administered until the patients is in an optimal plane that mimics natural sleep while spontaneously breathing to allow for a DISE evaluation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be administered until the patients is in an optimal plane that mimics natural sleep while spontaneously breathing to allow for a DISE evaluation
Study: NCT06758388

Intervention type: OTHER
Group type: OTHER
Intervention: home exercise program
Description: The prepared home exercise program is a program that includes gradual strengthening exercises that participants will do once a day, 5 days a week, for 8 weeks. The exercises will be performed as 1 set for the first 2 weeks, 2 sets in the 3rd and 4th weeks, and 3 sets in the last 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: home exercise program + brisk walking exercise
Description: In addition to the home exercise program applied by the control group, a brisk walk will be performed. The brisk walking exercise will be done for 30 minutes, 5 days a week for 8 weeks. The intensity of the exercise will be adjusted according to the Borg CR-10 scale and the Speech test. Moderate intensity exercise is recommended for participants. The participant will walk rhythmically for 30 minutes at a speed where he/she will give 4-6 points on the Borg CR-10 Scale, and can speak a few sentences without getting out of breath according to the Speech test, but cannot sing. Before and after the brisk walk, he/she will be asked to walk at a slow speed for 5 minutes (warm-up-cool down).
Study: NCT06757387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide and golidocitinib
Description: Enrolled patients will receive combination therapy with golidocitinib (150 mg QD or 150 mg QOD) and chidamide (20 mg BIW or 25 mg BIW)； If the MTD is determined at Dose Level 1 (chidamide 20 mg BIW / golidocitinib 150 mg QD), Dose Level 0 (chidamide 20 mg BIW / golidocitinib 150 mg QOD) will be further investigated. If the MTD is not established after escalating to Dose Level 2 (chidamide 25 mg BIW / golidocitinib 150 mg QD), the recommended Phase 2 dose (RP2D) will be determined through investigator consensus.
Study: NCT06757244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Intra-venous (i.v) dostarlimab: day1 - d21: 500mg IV q3Weeks (cycle 1 to cycle 4) then 1000 mg IV q6Weeks (from cycle 5 onwards)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (Cholecalciferol)
Description: Oral vitamin D3 8000 IU/d for 14 days, then 4000IU/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX Treatment Regimen
Description: mFOLFIRINOX d1, d15, d29 cycle 1 to cycle 4 is administered as follow: oxaliplatin 85 mg/m2 on day1, IV infusion over 2 h, immediately followed by folinic acid 400 mg/m2 or calcium levofolinate 200 mg/m2 given as a 2-h IV infusion, with the addition of irinotecan 180 mg/m2 as per dose-level given as a 90-min intravenous infusion through a Y-connector immediately followed by 5- fluorouracil 2400 mg/m2 over 46 h continuous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2
Description: folinic acid 400 mg/m2 Or calcium levofolinate 200 mg/m2 2-h IV infusion 5- fluoro-uracil 2400 mg/m2 Over 46 h continuous infusion. From cycle 5 onwards, D1=D43
Study: NCT06496568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Participants will receive inavolisib, 9 milligram (mg), PO, QD on Days 1-21 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Participants will receive inavolisib, 9 milligram (mg), PO, QD on Days 1-21 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab, 1200 mg, as IV infusion Q3W on Day 1 of each 21-day cycle.
Study: NCT06113640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa-carbidopa
Description: Carbidopa/levodopa, also known as levocarb and co-careldopa, is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa-carbidopa
Description: Carbidopa/levodopa, also known as levocarb and co-careldopa, is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease
Study: NCT06344156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy
Description: Gemcitabine +capecitabine, tislelizumab, neoantigen vaccines
Study: NCT05011526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901
Description: Approximately 471 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1222
Description: Approximately 471 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
Study: NCT05314959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician Awareness
Description: The patients' pre-visit Control Preference Scale responses are shared with their physician.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The patients' pre-visit Control Preference Scale responses are not shared with their physician.
Study: NCT06393881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UI059
Description: take UI059 once a day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UIC202201
Description: take UIC202201 once a day for 7 days
Study: NCT04900285

Intervention type: DEVICE
Group type: OTHER
Intervention: Delta Dental Oral Device
Description: The oral device is designed to move the genioglossus forward, with interior attachments to maintain the placement of the tongue on the floor of the mouth forward. In addition, bite plates made of the Ethylene-vinyl acetate (EVA) plastic were fabricated and embedded with the mouthpiece to encourage subjects to bite down and push the tongue under the interior lower attachment. The upper plate is made of the same material and slightly opens the bite to improve oral air flow further. The primary component of the mouthpiece is fabricated with Vistamaxx material, which is semi-crystalline 2mm co-polymer that can be molded by the user with Nurse assistance to provide a custom fit.~The subject will be fitted by moistening and heating in a microwave. Tthe research staff member will assist to ensure proper fit with both the lower and upper dental devices.~The subject then completes the data collection portion regarding using the SnoreLab app and survey completion as previously described.
Study: NCT05733078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: The patient in test group will be provided vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The patients who wish to continue at the end of 12 weeks will be provided another 12 weeks supply of vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for with thyroid function tests and clinical score assessed at the end of week 24.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Rehydration Salt Formulations
Description: The patients in control group will have a oral rehydration effervescent tablet to take with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The control group will then be provided vitamin C (intervention) effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks to see if there is any difference on biochemical testing or clinical scores.
Study: NCT06443762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga] MDM2/MDMX Peptide
Description: Utilizing a peptide with high affinity to MDM2/MDMX as the targeting moiety for radiopharmaceuticals, this study explores the diagnostic efficacy of \[68Ga\] MDM2/MDMX Peptide in patients with malignant tumors exhibiting high MDM2/MDMX expression. This approach not only provides a basis for the early diagnosis of malignant tumors but also facilitates the formulation of effective precision therapy strategies tailored to the tumor's MDM2/MDMX expression profile, particularly for patients with recurrent and metastatic disease.~\[68Ga\] MDM2/MDMX Peptide, a novel MDM2/MDMX-targeted molecular probe labeled with 68Ga, utilizes DOTA as a bifunctional chelator for complexing with 68Ga3+. The labeling process is straightforward, allowing for direct use without purification, and demonstrates high in vivo stability.
Study: NCT05814809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg tablet
Description: T : JP-1366 20mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg tablet
Description: T : JP-1366 20mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg capsule
Description: R : JP-1366 20mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg capsule
Description: R : JP-1366 20mg capsule
Study: NCT05963971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEDALL
Description: twenty-six hour nutrition education intervention delivered virtually over a six month period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Nutrition education per institutional standard of care
Study: NCT05243589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Description: Proprioceptive training included exercises on different floor textures composed of 10 stations of exercises with the objective of stimulating the sole of the foot where participants had to coordinate gait by stepping with alternate feet on markers placed on the ground and the progression was manipulated through modifications of speed and direction.~Sequence of materials was 10 cm-thick foam, wood box with beans, two-cm thick mat with a density lower than the foam, wood box with cotton, two-cm thick mat volunteers sat on a bench and trained feet flexors by grasping with the toes a towel put on the floor, Two proprioception balls was used with an eight cm diameter with external projections resting on the floor a box with grains and sandpaper. After that joint Positional Sense Exercises were performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine physical therapy
Description: Routine physical therapy included range of motion exercises for bilateral ankle joints (5 min.), functional balance training (15 min.) involving sit to stand (5 times); standing weight shift (5 times each); functional reach- sideway and anterior for touching targets set by the therapist (5 times each); bipedal heel rise for 20 seconds (5 times); unipedal standing for 15 seconds (5 times each) and unipedal standing with knee bending for 15 second (5 times each). Other exercises was practiced as wobble board training (6 min).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine physical therapy
Description: Routine physical therapy included range of motion exercises for bilateral ankle joints (5 min.), functional balance training (15 min.) involving sit to stand (5 times); standing weight shift (5 times each); functional reach- sideway and anterior for touching targets set by the therapist (5 times each); bipedal heel rise for 20 seconds (5 times); unipedal standing for 15 seconds (5 times each) and unipedal standing with knee bending for 15 second (5 times each). Other exercises was practiced as wobble board training (6 min).
Study: NCT06547073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality exercise training
Description: Beat saber

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality exercise training
Description: Beat saber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional exercise training
Description: Bench slides, supine active assisted flexion, pendulum exercise, seated active assisted external rotation
Study: NCT06113640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast and other CysLT1 antagonists are currently used as an adjuvant therapy for children and adults suffering from asthma. Other indications have been proposed and most evidence exists for the use of montelukast to treat allergic rhinitis, but its use in other inflammatory conditions, such as atherosclerosis and chronic obstructive pulmonary disease, have also been suggested.
Study: NCT05423847

Intervention type: DIAGNOSTIC_TEST
Intervention: POCUS
Description: POCUS of lungs, pericardium and abdomen

Intervention type: DIAGNOSTIC_TEST
Intervention: POCUS
Description: POCUS of lungs, pericardium and abdomen